Eliaz Therapeutics (adba ETI) is structured around continued development of a novel and selective extra-corporeal treatment for removal of Galectin-3 from the blood circulation and to reverse Chronic Kidney Disease, Fibrosis and Cancer. The device removes both bound and free galectin-3 from the circulation, offering a new treatment option that is less invasive and has fewer side-effects than other therapies. The single-use apheresis column selectively removes Galectin-3 from the body. It contains a proprietary, highly effective capturing molecule and is built in a format that hospitals already know how to use.Galectin-3 is of intensive research interest due to its pivotal role in numerous chronic diseases including cardiovascular, kidney, lung, and liver fibrosis, cancer progression and longevity. The device in development is designed to provide a new treatment option for different inflammatory and fibrotic diseases. The firm's first indication is Chronic Kidney Disease (CKD) highly prevalent and progressive with significant morbidity and mortality and currently no treatment to reverse the course of the disease is in the market.
